⌘K
t
On 19 March 2026, BSF Enterprise PLC announced that its subsidiary, 3D Bio-Tissues Limited (3DBT), entered into a five-year commercial Supply Agreement with South Korean biotechnology company SeaWith. The agreement, for the supply of 3DBT's proprietary City-Mix®, has an estimated total value of approximately £300,000 to 3DBT over the contract term. The announcement states City-Mix® is expected to lower SeaWith's production costs by reducing expensive growth media requirements by approximately 30%.
| Date | 19 Mar 2026 |
| Time | 07:00:04 |
| Category | Acquisitions and alliances |
| ID | 2085X |
19 March 2026
BSF Enterprise PLC
3D Bio-Tissues Limited ("3DBT")
Signs Commercial Supply Agreement with SeaWith
BSF Enterprise PLC (LSE: BSFA) (the "Company"), a leading innovator in tissue-engineered materials, is pleased to announce that its subsidiary, 3D Bio-Tissues Limited ("3DBT"), has entered into a five-year commercial Supply Agreement (the "Agreement") with SeaWith, a pioneering South Korean biotechnology company specializing in cultivated meat.
Strategic Partnership and Value Creation
The Agreement establishes a long-term commercial framework for the supply of 3DBT's proprietary City-Mix®, a premium macromolecular crowder designed to enhance cell culture efficiency. This partnership represents a significant milestone in expanding the market reach of City-Mix® into the global cultivated protein sector.
· Contract Value: The total value of the Agreement to 3DBT is estimated at approximately £300,000 over the contract term.
· Operational Integration: 3DBT will provide a regular supply of City-Mix® to support SeaWith's production pipeline for its flagship Welldone™ cultivated beef product.
· Cost Efficiency: City-Mix® is expected to significantly lower production costs for SeaWith by reducing the requirement for expensive growth media by approximately 30%.
· Growth Trajectory: The Agreement supports a phased scale-up of supply volumes through 2030, aligning with SeaWith's transition toward large-scale commercial production facilities.
About SeaWith
Founded in 2019 and headquartered in South Korea, SeaWith is a biotechnology innovator that has raised over $8 million in venture funding to date. The company utilizes seaweed-derived technologies to produce sustainable, slaughter-free meat alternatives, focusing on scalability and the reduction of environmental impact. SeaWith is a designated operator under South Korea's Gyeongbuk Cell-Cultured Food Regulatory Free Zone, reflecting the company's leadership in advancing cultivated food innovation within a government-supported regulatory framework.
END
Engage with the BSF Enterprise management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor
website here:
https://bsfenterprise.com/link/Pqnkoy
For further enquiries, please visit www.bsfenterprise.com or contact:
|
BSF Enterprise PLC Geoff Baker - Chairman Che Connon - CEO & Director
We encourage all investors to share questions on this announcement via our investor website. |
|
|
Shard Capital (Broker) Damon Heath Isabella Pierre |
(0)20 4530 6926 (0)20 4530 6928 |
|
ISIN of the Ordinary Shares is GB00BHNBDQ51. SEDOL Code is BHNBDQ5. |
|
Subscribe to our news alert service: https://bsfenterprise.com/s/bb9f43
About BSF Enterprise PLC
BSF Enterprise PLC (LSE:BSFA) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather (via LGL), cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free ATEP™ platform, BSF delivers sustainable, high-performance alternatives to conventional materials, targeting global markets where provenance, ethics, and performance are increasingly prized by consumers and brands alike.